BioWorld Asia

Nov. 1, 2006

View Archived Issues

CAT's Humira Royalty Sold By AstraZeneca For $700M

LONDON - AstraZeneca plc, the new owner of Cambridge Antibody Technology Group (CAT) Ltd., sold the royalty rights to the antibody company's one marketed product, Humira, for $700 million. (BioWorld International) Read More

Hold On Paion's Desmoteplase Lifted; Phase III Back On Track

Read More

Schizophrenia Gene Study Reveals Influence On Brain

Read More

Ethics Questions Delay Europe's Decision On Advanced Therapies

Read More

Cytheris' €24M Series B Round Should Fuel Company Into 2009

No Abstract Read More

Innate Planning For IPO, Seeking €25M To €€36M

No Abstract Read More

LibraGen Enters Research Deal With Sanofi-Aventis

Read More

Renovo Reports Positive Data In Third Juvista Phase II Trial

Read More

Other News To Note

Read More